A Study of BGM0504 in Early T2DM With Obesity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 372 participants.

Also called NCT07743983

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 372 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07743983
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07743983. Randomized; no masking; primary purpose treatment. Start 2026-09-17 (actual); primary completion 2028-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of BGM0504 in Early T2DM With Obesity
Condition
Type 2 Diabetes (T2DM)
Intervention (Drug)
BGM0504
Intervention (Drug)
semaglutide
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07743983
Content hash
6e4454f8f5bb4678f0027795ae48d185e92f5c92706435aa6513e3c8be1581e8